Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

The effects of conjugate and light dose on photo-immunotherapy induced cytotoxicity

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1Email author
BMC Cancer201414:389

https://doi.org/10.1186/1471-2407-14-389

©  Nakajima et al.; licensee BioMed Central Ltd. 2014

  • Received: 18 March 2014
  • Accepted: 20 May 2014
  • Published:
Open Peer Review reports

Abstract

Background

Photoimmunotherapy (PIT) is a highly cell-selective cancer therapy, which employs monoclonal antibodies conjugated to a potent photosensitizer (mAb-IR700). Once the conjugate has bound to the target cell, exposure to near infrared (NIR) light induces necrosis only in targeted cells with minimal damage to adjacent normal cells in vivo. Herein, we report on the effect of altering mAb-IR700 and light power and dose on effectiveness of PIT.

Methods

For evaluating cytotoxicity, we employed ATP-dependent bioluminescence imaging using a luciferase-transfected MDA-MB-468luc cell line, which expresses EGFR and luciferase. In in vitro experiments, panitumumab-IR700 (Pan-IR700) concentration was varied in combination with varying NIR light doses administered by an LED at one of three power settings, 100 mA and 400 mA continuous wave and 1733 mA intermittent wave. For in vivo experiments, the MDA-MB-468luc orthotopic breast cancer was treated with varying doses of Pan-IR700 and light.

Results

The in vitro cell study demonstrated that PIT induced cytotoxicity depended on light dose, when the conjugate concentration was kept constant. Increasing the dose of Pan-IR700 allowed lowering of the light dose to achieve equal effects thus indicating that for a given level of efficacy, the conjugate concentration multiplied by the light dose was a constant. A similar relationship between conjugate and light dose was observed in vivo.

Conclusions

The efficacy of PIT is defined by the product of the number of bound antibody conjugates and the dose of NIR light and can be achieve equally with continuous and pulse wave LED light using different power densities.

Keywords

  • Photoimmunotherapy
  • Near infrared light
  • Light dose
  • Necrosis
  • Cytotoxicity

Background

Photoimmunotherapy (PIT) is a highly cell-selective cancer therapy, which utilizes a monoclonal antibody (mAb) conjugated to the photosensitizing phthalocyanine dye, IRDye700DX (IR700). After intravenous injection, mAb-IR700 conjugates preferentially to cancer cells expressing the proper antigen and subsequent exposure of the cells to near infrared (NIR) light induces highly selective and rapid cell necrosis. An attractive feature of PIT is that minimal damage is seen in adjacent normal cells [1]. The effectiveness of PIT appears generalizable across a number of different types of cancers and with multiple mAb-IR700 conjugates [2]. When the mAb-IR700 conjugate is well matched to the target tumor, exposure to NIR light results in rapid and severe damage to the cell membrane inducing necrotic cell death within a minute [3]. However, the relationship between the dose of mAb-IR700 and the dose or power density of NIR light has not been fully investigated. Optimized dosing of NIR light exposure is critical for planning a successful clinical trial of PIT in both therapeutic efficacy and patient safety.

PIT induces cell death by necrosis that releases ATP from cells, which is quickly hydrolyzed. Thus, we employed ATP-dependent bioluminescence imaging of firefly luciferase transfected cells as a readout of the effectiveness of PIT while varying the dose of the mAb-IR700 and NIR light that was proven to be a more accurate biomarker for accessing acute PIT effects than tumor size especially within 3 days after PIT [4, 5].

Methods

Reagents

Panitumumab, a fully humanized IgG2 monoclonal antibody (mAb) directed against human EGFR was purchased from AMGEN Inc. (Thousand Oaks, CA). A water soluble,silicon-based-phthalocyanine dye derivative, IRDye 700DX NHS ester (IR700; C74H96N12Na4O27S6Si3, molecular weight of 1954.22), was obtained from LI-COR Bioscience (Lincoln, NE). All other chemicals used were of reagent grade.

Synthesis of IR700-conjugated Panitumumab

Panitumumab (1 mg, 6.8 nmol) was incubated with IR700 (66.8 μg, 34.2 nmol, 5 mmol/L in DMSO) in 0.1 mol/L Na2HPO4 (pH 8.5) at room temperature for 1 h. Then the mixture was purified with a Sephadex G50 column (PD-10; GE Healthcare, Piscataway, NJ). The protein concentration was determined with a Coomassie Plus protein assay kit (Pierce Biotechnology, Rockford, IL) by measuring the absorption at 595 nm (8453 Value System; Agilent Technologies, Santa Clara, CA). The concentration of IR700 was measured by its absorption to confirm the number of fluorophore molecules conjugated to each Panitumumab molecule. The number of IR700 per antibody was approximately 4 for the 1:4.5 reaction conditions. The resulting compound, Pan-IR700, was kept at 4°C as a stock solution.

Cell line

EGFR-expressing MDA-MB-468luc, [6] stable luciferase-transfected cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in tissue culture flasks using a humidified incubator at 37°C in an atmosphere of 95% air and 5% carbon dioxide.

Fluorescence microscopy

To detect the antigen specific localization of Pan-IR700, fluorescence microscopy was performed (BX61; Olympus America, Melville, NY). MDA-MB-468luc was seeded on cover-glass-bottomed dishes and incubated for 16 h. Pan-IR700 conjugate (10 μg/mL) was added to the culture medium and incubated for 6 h at 37°C, followed by washing with PBS. The filter was set to detect IR700 fluorescence with a 590–650 nm excitation filter and a 665–740 nm band pass emission filter.

Phototoxicity assay

Cytotoxicity of PIT was determined by measuring luciferase activity and by quantitative flow cytometry using propidium iodide (PI) as a stain for dead cells. For the luciferase activity assay, d-luciferin (150 μg/ml, Gold Biotechnology, St. Louis, MO) was added to the culture medium and bioluminescence (signal intensity) was detected (Photon Imager; Biospace Lab, Cambridge, MA). For the flow cytometry assay, cells were trypsinized after treatment, washed with PBS and 1 μL of PI (5 mg/mL) was added to the cell suspension which was vortexed. Cells were analyzed on a flow cytometer (FACS Calibur; BD BioSciences, San Jose, CA).

In vitrophotoimmunotherapy

Cells were seeded on a 96 well plate or 35 mm cell culture dishes and incubated for 8 h at 37°C. The culture medium was refreshed and 10 μg/mL of Pan-IR700 was added over night. After washing with PBS, phenol red free culture medium was added. Then, cells were irradiated with a red light-emitting diode (LED), which emits light at 670 to 710 nm wavelength (L690-66-60; Marubeni America Co., New York, NY), controlled by FluorVivo software (INDEC Systems, Santa Clara, CA) at a current of 100 mA (continuous-wave; CW), 400 mA (CW) and 1733 mA (pulse-wave; PW). The pulse wave duration was 0.2 ms separated by 0.8 ms so that the pulse occurred every 1 ms (Figure 1). The power density of the LED was 12.5 mW/cm2 at 100 mA CW and 25 mW/cm2 at 400 mA CW and 1733 mA PW as measured with an optical power meter (PM 100; Thorlabs, Newton, NJ).
Figure 1
Figure 1

Schematic sequences of LED irradiation. (A) Pulse wave (PW) lighting is achieved via peak currents of 1733 mA. (B) Continuous wave (CW) lighting at 400 mA and 100 mA. (C) The irradiation times were 20 min for the 1733 mA (PW) and 400 mA (CW) and it took 40 min for irradiation at 100 mA (CW). Total irradiation dose of these three groups was adjusted to 30 J/cm2. (D) Photograph of LED lights, left; 1733 mA (PW), right; 400 mA (CW).

MDA-MB-468luc cells were irradiated at 0.2, 0.5, 2 and 5 J/cm2 using all 3 power settings (100 mA CW, 400 mA CW and 1733 mA PW). Cell viability was analyzed with flow cytometry and bioluminescence imaging.

Pan-IR700 was added to cells at concentrations of 0.3, 1, 3, 10 μg/mL. Cells were incubated for 8 h followed by washing once with PBS and restoration of phenol red free culture medium. The cells were then irradiated with the LED light of 400 mA (CW) at a total dose of 2 J/cm2. In vitro treatments for cells were performed using the following combinations of Pan-IR700 and NIR light dose: (1) 3 μg/mL and 0.5 J/cm2, (2) 1 μg/mL and 1.5 J/cm2, and (3) 0.3 μg/mL and 5 J/cm2.

Tumor model

All procedures were carried out in compliance with the Guide for the Care and Use of Laboratory Animal Resources (1996), National Research Council, and approved by the local Animal Care and Use Committee. Six- to eight-week-old female homozygote athymic nude mice were purchased from Charles River (NCI-Frederick, Frederick, MD). During the procedure, mice were anesthetized with isoflurane. MDA-MB-468luc cells (2 × 106 cells) were injected subcutaneously into the right mammary pads of the mice. The experiments were conducted 2 weeks after MDA-MB-468luc cell implantation.

In vivophotoimmunotherapy with different power levels of LED light

Orthotopic breast tumors were irradiated at all three power settings, 100 mA (CW), 400 mA (CW) and 1733 mA (PW). Total irradiation doses were 30 J/cm2 with power density of 200 mW/cm2. Mice images were acquired with a fluorescence imager (Pearl Imager; LI-COR Biosciences) for detecting IR700 fluorescence, and Photon Imager for BLI. BLI was used for evaluation of PIT effects. Regions of interest (ROIs) were placed over the entire tumor and photon numbers were counted for each ROI.

Statistical analysis

Statistical analysis was performed using a statistics program (GraphPad Prism6, GraphPad Software, La Jolla, CA). A one-way analysis of variance (ANOVA) was used to compare differences in responses to level of light exposure among the three groups. Pearson’s correlation coefficient was used to analyze the correlation between the dead cell ratio and the concentrations of Pan-IR700. Values of p < 0.05 were considered statistically significant.

Results

Target specific binding of Pan-IR700 to EGFR on fluorescence microscopy

Fluorescence microscopy was performed to confirm target-specific localization of Pan-IR700. Fluorescence was mainly localized to the cell membrane and lysosomes of the cells. During continuous NIR light exposure the cells demonstrated almost immediate swelling, budding and rupture of the membrane was observed leading to irreversible cell death (Figure 2).
Figure 2
Figure 2

Sequential microscopic images of MDA-MB-468luc cells treated with Pan- IR700 (images before (left), during (middle) and after (right) irradiation, upper images; DIC images, lower images; fluorescence images). PIT induced cell death with swelling, budding and rupture of the membrane as shown on the DIC images (middle and right). Fluorescence signals decreased after continuous NIR irradiation. Scale bar: 50 μm (original magnification, ×400).

Effect of phototoxicity in response to Pan-IR700 mediated PIT

Flow cytometry showed that the ratio of dead cells increased from ~40 to ~85% as the light dose increased from 0.2 to 5 J/cm2 at every LED light power; 100, 400 and 1733 mA. At each light dose, no significant difference was observed in rate of cell death was seen among the 3 power levels (Figure 3A, 0.2 J/cm2: p > 0.05, 0.5 J/cm2: p > 0.05, 2 J/cm2: p > 0.05, 5 J/cm2: p = 0.014). Low levels of LED light irradiation dose (0.2 J/cm2) demonstrated relatively high bioluminescence signals. Bioluminescence signals decreased as exposure to NIR light dose increased. Bioluminescence signals were similar among the 3 different power levels at the same light dose (see Figure 3B, 0.2 J/cm2: p > 0.05, 0.5 J/cm2: p > 0.05, 2 J/cm2: p > 0.05, 5 J/cm2: p = 0.036). Larger doses of NIR light (5 J/cm2) resulted in correspondingly lower bioluminescence signals.
Figure 3
Figure 3

Effect of phototoxicity in response to Pan-IR700 mediated PIT. Cell viability was analyzed with (A) flow cytometory with dead staining using PI and (B) bioluminescence after LED light irradiation in MDA-MB-468luc cells. (n = 3, n.s. p > 0.05, *p < 0.05).

Correlation between the concentration of Pan-IR700 and the irradiation dose

A positive monoexponential correlation was seen between concentrations of Pan-IR700 ranging from 0.3 to 3 μg/mL and the cell death rate at a constant NIR light dose of 2 J/cm2 (Figure 4A, R2 = 0.94). Next we defined the effective dose parameter (1.5 J・μg/mL・cm2) by multiplying the Pan-IR700 concentration by the light dose. The cell death rate of the following combinations: (1) 3 μg/mL and 0.5 J/cm2, (2) 1 μg/mL and 1.5 J/cm2, and (3) 0.3 μg/mL and 5 J/cm2) showed no significant difference (Figure 4B, p > 0.05). The correlation between the light dose and the concentration of Pan-IR700 fit the following equation: [concentration of Pan-IR700 (μg/mL)] = 9.65e^-1.15 [irradiation dose (J/cm2)] (Figure 4C).
Figure 4
Figure 4

Correlation between the concentration of Pan-IR700 and light dose for cell killing. (A) At as constant light dose of 2 J/cm2, as the concentration of Pan-IR700 increased from 0.3 to 3 μg/mL, the percentage of dead cells increased. There was a positive linear correlation on a log scale between increasing dose and cell killing at a constant light dose (R2 = 0.94). Note, that above 3 μg/mL no further increases in cell death are seen due to saturation of the membrane antigens. (B) The same rate of cell killing (measured by bioluminescence imaging) could be achieved by any of the following combinations: (1) 3 μg/mL and 0.5 J/cm2, (2) 1 μg/mL and 1.5 J/cm2, and (3) 0.3 μg/mL and 5 J/cm2) resulting in no significant difference among these three groups (p > 0.05). (C) The correlation between light dose and the concentration of Pan-IR700 derived the following equation: [concentration of Pan-IR700] = 9.65e^-1.15 [irradiation dose]. The product of the light dose (in J/cm2) and the concentration of Pan-IR700 (in μg/mL) is a constant of 1.5.

In vivophotoimmunotherapy assessed by bioluminescence imaging

All NIR light exposure of 30 J/cm2 with three different light power levels (100 mA CW, 400 mA CW and 1733 mA PW) induced decreased bioluminescence signals of PIT-treated tumor compared with the pre-treated tumor. Bioluminescent photon counts of all these three groups decreased 61.4%; 100 mA (CW) 61% (400 mA (CW), 61.5%; 1733 mA (PW), 61.4%) 1 day after NIR light exposure (Figure 5).
Figure 5
Figure 5

In vivo photoimmunotherapy in orthotopic breast tumors with a constant dose of 30 J/cm 2 delivered by 100 mA (CW), 400 mA (CW) and 1733 mA (PW) LED light. (A) Photon counts on bioluminescence images of tumors before and 1 day after LED irradiation. Photon counts of tumors in these three groups decreased around 60% (400 mA (CW), 60.1%; 100 mA (CW), 60.1%; 1733 mA (PW), 60.1%) 1 day after LED irradiation. (B) In vivo fluorescence (upper row) and bioluminescence imaging (lower row) of orthotopic breast tumors before and 1 day after Pan-IR700 mediated PIT.

Discussion

These data demonstrate that increased cytotoxicity with PIT can be achieved by either increasing the dose of the mAb-IR700 (up to the saturating dose) or increasing the dose of light (up to the thermal limits). Moreover, a constant level of cell killing can be achieved by modulating the doses of both the conjugate and the light dose. These data also demonstrate that the power density (mW/cm2) of the light source is not as critical a factor as is the light dose (J/cm2) in determining the effectiveness of PIT. Moreover, the effect of a given light dose is independent of the manner in which the light is delivered, that is, either continuously or intermittently. Only at the relatively high light dose of 5 J/cm2, was a significant difference seen in dead staining and bioluminescence, among three power settings probably due to the long exposure times required to reach such a high light dose with low power NIR light (100 mA).

In addition to the effect of light dose, these data confirm that increasing concentrations of Pan-IR700 induced more cell death at a fixed light dose (2 J/cm2) (Figure 4A). However, above a concentration of 3 μg/mL of Pan-IR700 no further increases in cell death were seen suggesting that the EGFR antigens on the MDA-MB-468luc cell surface were saturated with Pan-IR700 at 3 μg/mL and therefore, higher doses did not result in further effectiveness (Figure 4).

MDA-MB-468 orthotopic breast tumors in mice administered Pan-IR700 showed ~60% decrease of bioluminescence signals after 30 J/cm2 of NIR light exposure. In vivo cytotoxicity data confirmed in vitro data that PIT-induced cytotoxicity is related to the product of the dose of the conjugate (up to the saturating dose) and the light dose.

In order to decrease either the dose of the conjugate or the light dose and achieve similar results, the spectral profile of the light source would need to be improved. In this study, we used an LED which emitted 690 ± 20 nm of NIR light. However, the absorbance spectrum of IR700 around 690 nm is sharper than the emission spectrum of this LED. Therefore, a large proportion of the exposed energy was not absorbed by IR700. Theoretically, we could improve the quantum efficiency of the light dose by using a laser light source tuned to emit a single 690 nm wavelength of light (± 5 nm).

Fluorescent proteins (FPs) are an excellent method for monitoring preclinical tumor growth in vivo[7–10]. FPs are stable and therefore ideal for longitudinal monitoring of photo-induced cancer therapies as has been shown previously [11, 12]. However, FPs keep glowing before they are taken up and catabolized by macrophages in vivo[13] that takes hours after cell death [7]. In the current application the rapidity, with which PIT induces cell death, is difficult to detect with FPs as fluorescence would persist after cell death especially in vitro. Because firefly luciferin-based bioluminescence is an ATP-dependent process and ATP is released from damaged cells and hydrolyzed during or shortly after PIT, bioluminescence imaging is theoretically and practically an appropriate method for detecting in vivo PIT-induced cell necrosis [4]. Furthermore, FPs are excellent endogenous fluorescence emitters and/or singlet oxygen producers for operating as photo-dynamic therapy (PDT) agents. For selectively targeting cancer, recently reported technology is the use of telomerase promoter-regulated expression of various fluorescent proteins, which are induced with adenovirus-mediated gene transfection in vivo[11, 12, 14, 15]. However, the requirement for virus-mediated in vivo gene transfection makes it unlikely to be translated for human use in the near term. In contrast, the PIT technology described here should be readily translatable as it requires the injection of an antibody-IR700 conjugate and exposure to non-thermal levels of NIR light.

Conclusion

We demonstrate that cell killing with PIT is dependent on conjugate dose, up to the saturating dose, and the light dose. We found that a constant level of cell death could be achieved by varying the conjugate dose and light dose in such a way that the product was a constant. At a defined conjugate-light dose product, the cytotoxic effect of PIT is the same regardless of how the light is delivered (continuously or intermittently). This result suggests that the cytotoxic effect induced by PIT, which depends on the number of bound mAb-IR700 molecules and the exposed light dose, is highly predictable. Since the number of bound mAb-IR700 conjugates is roughly proportional to the intensity of IR700 fluorescence, this value could be used to calculate the appropriate effective and safe light dose in the future.

Abbreviations

PIT: 

Photoimmunotherapy

NIR: 

Near infrared

mAb: 

Monoclonal antibody

FDA: 

Food and Drug Administration

CW: 

Continuous-wave

PW: 

Pulse-wave

LED: 

Light-emitting diode

ROI: 

Regions of interest.

Declarations

Acknowledgements

This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.

Authors’ Affiliations

(1)
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Bldg. 10, Room B3B69, MSC 1088, Bethesda, Maryland 20892-1088, USA

References

  1. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H: Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011, 17: 1685-1691. 10.1038/nm.2554.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Nakajima T, Sano K, Choyke PL, Kobayashi H: Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics. 2013, 3: 357-365. 10.7150/thno.5908.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Mitsunaga M, Nakajima T, Sano K, Choyke PL, Kobayashi H: Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem. 2012, 23: 604-609. 10.1021/bc200648m.View ArticlePubMedGoogle Scholar
  4. Mitsunaga M, Nakajima T, Sano K, Kramer-Marek G, Choyke PL, Kobayashi H: Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. BMC Cancer. 2012, 12: 345-10.1186/1471-2407-12-345.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Sano K, Mitsunaga M, Nakajima T, Choyke PL, Kobayashi H: Acute Cytotoxic Effects of Photoimmunotherapy Assessed by 18 F-FDG PET. J Nucl Med. 2013, 54: 770-775. 10.2967/jnumed.112.112110.View ArticlePubMedGoogle Scholar
  6. Lyakhov I, Zielinski R, Kuban M, Kramer-Marek G, Fisher R, Chertov O, Bindu L, Capala J: HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging. Chembiochem. 2010, 11: 345-350. 10.1002/cbic.200900532.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Hoffman RM: The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer. 2005, 5: 796-806. 10.1038/nrc1717.View ArticlePubMedGoogle Scholar
  8. Hoffman RM, Yang M: Subcellular imaging in the live mouse. Nat Protoc. 2006, 1: 775-782. 10.1038/nprot.2006.109.View ArticlePubMedGoogle Scholar
  9. Jiang P, Yamauchi K, Yang M, Tsuji K, Xu M, Maitra A, Bouvet M, Hoffman RM: Tumor cells genetically labeled with GFP in the nucleus and RFP in the cytoplasm for imaging cellular dynamics. Cell Cycle. 2006, 5: 1198-1201. 10.4161/cc.5.11.2795.View ArticlePubMedGoogle Scholar
  10. Yamamoto N, Jiang P, Yang M, Xu M, Yamauchi K, Tsuchiya H, Tomita K, Wahl GM, Moossa AR, Hoffman RM: Cellular dynamics visualized in live cells in vitro and in vivo by differential dual-color nuclear-cytoplasmic fluorescent-protein expression. Cancer Res. 2004, 64: 4251-4256. 10.1158/0008-5472.CAN-04-0643.View ArticlePubMedGoogle Scholar
  11. Kimura H, Lee C, Hayashi K, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Bouvet M, Hoffman RM: UV light killing efficacy of fluorescent protein-expressing cancer cells in vitro and in vivo. J Cell Biochem. 2010, 110: 1439-1446. 10.1002/jcb.22693.View ArticlePubMedGoogle Scholar
  12. Tsai MH, Aki R, Amoh Y, Hoffman RM, Katsuoka K, Kimura H, Lee C, Chang CH: GFP-fluorescence-guided UVC irradiation inhibits melanoma growth and angiogenesis in nude mice. Anticancer Res. 2010, 30: 3291-3294.PubMedGoogle Scholar
  13. Shimomura O: Discovery of green fluorescent protein (GFP) (Nobel Lecture). Angew Chem Int Ed Engl. 2009, 48: 5590-5602. 10.1002/anie.200902240.View ArticlePubMedGoogle Scholar
  14. Momiyama M, Suetsugu A, Kimura H, Kishimoto H, Aki R, Yamada A, Sakurada H, Chishima T, Bouvet M, Bulgakova NN, Endo I, Hoffman RM: Fluorescent proteins enhance UVC PDT of cancer cells. Anticancer Res. 2012, 32: 4327-4330.PubMedGoogle Scholar
  15. Momiyama M, Suetsugu A, Kimura H, Kishimoto H, Aki R, Yamada A, Sakurada H, Chishima T, Bouvet M, Endo I, Hoffman RM: Imaging the efficacy of UVC irradiation on superficial brain tumors and metastasis in live mice at the subcellular level. J Cell Biochem. 2013, 114: 428-434. 10.1002/jcb.24381.View ArticlePubMedGoogle Scholar

    16. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/389/prepub

Copyright

© Nakajima et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us